Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smart insulin pump outsmart pizza? a trial puts it to the test

NCT ID NCT07786064

Disease control Sponsor: Konstantinos Makrilakis, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This study compares two insulin pump systems in adults with type 1 diabetes to see which better controls blood sugar after eating a high-fat meal like pizza. The newer closed-loop pump automatically gives small insulin corrections every 5 minutes, while the older open-loop pump allows a special dual-wave bolus pattern. Researchers will measure blood glucose levels over 4 hours after the meal to see how well each approach manages the late blood sugar spike that high-fat foods often cause.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Comparison of two insulin pump systems: the Medtronic MiniMed 640G (open-loop) and the Medtronic MiniMed 780G (hybrid closed-loop), both delivering insulin via continuous subcutaneous infusion.
What this could lead to
If the closed-loop pump handles high-fat meals well, it could simplify mealtime management for people with type 1 diabetes, reducing the need for complex bolus calculations.
What could go wrong
This is a small, early-stage study (20 participants) and results may not apply to all patients. The closed-loop pump lacks a dual-wave bolus feature, which might limit its effectiveness for high-fat meals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Jun 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Type 1 Diabetes (T1D) at least 12 months prior to study participation * Use of continuous subcutaneous insulin infusion (CSII) pump for at least 6 months prior to enrollment ("trained" patients) * Adequate glycemic control (recent HbA1c value ≤ 8%) Exclusion Criteria: * Known microvascular and macrovascular complications of diabetes * History of gastroparesis or malabsorption * History of stomach or intestinal surgery * Use of medications that affect gastrointestinal motility (e.g., prokinetics, antiemetics, GLP-1 agonists, etc.) * Known deficiency of fat-soluble vitamins (A, D, E, K)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes mellitus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes mellitus

Contacts and locations

Locations

  • Diabetes Laboratory, 1st Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens Medical School, Laiko General Hospital, Athens, Greece

    Athens, Athens, 11527, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.